Literature DB >> 31576339

Cardiovascular and renal protection with sodium-glucose cotransporter type 2 inhibitors: new paradigm in type 2 diabetes management…and potentially beyond.

André J Scheen1,2.   

Abstract

Entities:  

Year:  2019        PMID： 31576339      PMCID： PMC6685897          DOI： 10.21037/atm.2019.05.82

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  25 in total

Review 1.  An update on the safety of SGLT2 inhibitors.

Authors:  André J Scheen
Journal:  Expert Opin Drug Saf       Date:  2019-04-16       Impact factor: 4.250

2.  Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable.

Authors:  Francesco Cosentino; Antonio Ceriello; Florian M M Baeres; Paola Fioretto; Alan Garber; Wendy Gattis Stough; Jyothis T George; Peter J Grant; Kamlesh Khunti; Anna Maria Langkilde; Jorge Plutzky; Lars Rydén; André Scheen; Eberhard Standl; Jaakko Tuomilehto; Faiez Zannad
Journal:  Eur Heart J       Date:  2019-09-07       Impact factor: 29.983

Review 3.  Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.

Authors:  André J Scheen
Journal:  Diabetes Res Clin Pract       Date:  2018-06-23       Impact factor: 5.602

4.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Authors:  Thomas A Zelniker; Stephen D Wiviott; Itamar Raz; Kyungah Im; Erica L Goodrich; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Remo H M Furtado; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Marc S Sabatine
Journal:  Lancet       Date:  2018-11-10       Impact factor: 79.321

5.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Thomas A Zelniker; Julia F Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna-Maria Langkilde; Marc S Sabatine
Journal:  N Engl J Med       Date:  2018-11-10       Impact factor: 91.245

Review 6.  Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.

Authors:  A J Scheen
Journal:  Diabetes Metab       Date:  2018-10-25       Impact factor: 6.041

Review 7.  Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Drugs       Date:  2015-01       Impact factor: 9.546

Review 8.  Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.

Authors:  Ralph A DeFronzo; Luke Norton; Muhammad Abdul-Ghani
Journal:  Nat Rev Nephrol       Date:  2016-12-12       Impact factor: 28.314

Review 9.  Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.

Authors:  André J Scheen
Journal:  Circ Res       Date:  2018-05-11       Impact factor: 17.367

10.  Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Melanie J Davies; David A D'Alessio; Judith Fradkin; Walter N Kernan; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Apostolos Tsapas; Deborah J Wexler; John B Buse
Journal:  Diabetes Care       Date:  2018-10-04       Impact factor: 19.112
View more
  2 in total

Review 1.  Impact of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging-What Do We Know So Far? (A Narrative Review).

Authors:  Cristina Andreea Adam; Razvan Anghel; Dragos Traian Marius Marcu; Ovidiu Mitu; Mihai Roca; Florin Mitu
Journal:  Life (Basel)       Date:  2022-05-27

2.  No Relevant Pharmacokinetic Drug-Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects.

Authors:  Yu Kyong Kim; Jun Gi Hwang; Min Kyu Park
Journal:  Drug Des Devel Ther       Date:  2021-04-28       Impact factor: 4.162
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.